| Description | DL-Laudanosine (Laudanosine) is a recognized metabolite of atracurium and cisatracurium. |
| In vivo | laudanosine, a metabolite of atracurium and a central nervous system stimulant, might increase the minimum alveolar concentration (MAC) of halothane.?These estimates were used to determine the rates of infusion that would produce steady state plasma concentrations of laudanosine of approximately 200, 400, and 800 ng .?ml-1.?Subsequent infusion of laudanosine in eight rabbits produced mean (+/- SD) steady state plasma concentrations of laudanosine of 234 +/- 56, 457 +/- 66, and 873 +/- 105 ng .?ml-1.?The control value for MAC of halothane was 1.08 +/- 0.28%.?At the lowest steady state plasma laudanosine concentration, MAC did not significantly differ from control (MAC = 1.15 +/- 0.23%, P less than 0.1).?However, at 457 and 873 ng .?ml-1, laudanosine significantly increased the MAC of halothane by 23% and 30%, respectively.?Infusion with saline in two additional rabbits did not affect MAC. Therefore, at the plasma concentrations of laudanosine found in humans after administration of atracurium, laudanosine increased the MAC of halothane in rabbits[1]. |
| Synonyms | Laudanosine, DL-劳丹素 |
| molecular weight | 357.44 |
| Molecular formula | C21H27NO4 |
| CAS | 1699-51-0 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 11 mg/mL (30.77 mM) |
| References | 1. Shi W Z , Fahey M R , Fisher D M , et al. Laudanosine (A Metabolite of Atracurium) Increases the Minimum Alveolar Concentration of Halothane in Rabbits[J]. Anesthesiology, 1985, 63(6):584-588. 2. Katz Y , Weizman A , Pick C G , et al. Interactions between laudanosine, GABA, and opioid subtype receptors: implication for laudanosine seizure activity[J]. brain research, 1994, 646(2):0-241. |